Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Khadega A. Abuelgasim
Chemoimmunotherapy With Brentuximab Vedotin Combined With Ifosfamide, Gemcitabine, and Vinorelbine Is Highly Active in Relapsed or Refractory Classical Hodgkin Lymphoma
Bone Marrow Transplantation
Transplantation
Hematology
Related publications
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin
British Journal of Haematology
Hematology
Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia
OncoTargets and Therapy
Oncology
Pharmacology
Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma
Blood and Lymphatic Cancer: Targets and Therapy
Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience
Acta Haematologica Polonica
Oncology
Hematology
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Investigating Safety and Preliminary Efficacy of Afm13 Plus Pembrolizumab in Patients With Relapsed/Refractory Hodgkin Lymphoma After Brentuximab Vedotin Failure
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
